Systematic review indicates increased risk of breast cancer after thyroid cancer, suggesting significant implications for patient management.
Thyroid cancer (TC) and breast cancer (BC) are common in females, with growing evidence of their higher-than-expected co-occurrence. The purpose of this systematic review and meta-analysis was to evaluate the relationship between TC and BC, and to examine the likelihood of developing BC after TC (TC1-BC2) and TC after BC (BC1-TC2). A systematic search was conducted in PubMed and Embase for articles with epidemiological evidence of TC and BC, published until 2024. For BC1-TC2 studies, subgroup analysis was performed on age at diagnosis and treatment type. The standardized incidence ratio (SIR) was used to calculate the risk of second primary malignancy (SPM). The MOOSE guidelines were followed, and the Newcastle–Ottawa Scale was used to assess the quality of studies. Sixteen studies comprising 511,787 patients were included in the meta-analysis of TC1-BC2 and showed an increased risk of BC after TC (SIR = 1.4, 95% CI 1.2-1.6, p<0.01). Moreover, 28 studies with 2,486,870 patients were included for BC1-TC2 meta-analysis and also demonstrated an increased risk of TC after BC (SIR = 1.5, 95% CI 1.3-1.7, p<0.01). The risk of TC was higher in BC patients under 50 (SIR = 1.8, 95% CI 1.2-2.3) and those treated with chemotherapy (SIR = 1.6, 95% CI 1.5-1.7). Radiotherapy for BC was not linked to an increased risk of TC. Here we demonstrated an increased risk of TC or BC as secondary malignancies. Further studies are needed to better understand this association and its implications on patient follow-up and management strategies.
No takes yet. Share an insight, caveat, or question.
Viola et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: